Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome
April 19, 2023
Coverage recommandation for our innovative IVD test METAglut™ by French National Authority for Health (HAS)
May 3, 2023
April 27, 2023.
[NEWS] Company ; METAglut1™
We are pleased to announce that the Haute Autorité de Santé (HAS) – the french National Authority for Health – has published an article evaluating our innovative in vitro diagnostic test, METAglut1™.
METAglut1™ is our first IVD blood test designed to aid in the early diagnosis of Glut1 Deficiency Syndrome (Glut1DS), also known as De Vivo Disease. This rare neuro metabolic disorder can have a profound impact on the lives of affected children.
We believe that our diagnostic tool represents a significant advancement in identifying the condition, which can have profound implications for affected individuals and their families.
This publication underscores the significance of our test in the clinical landscape for diagnosing GLUT1 deficiency syndrome (GLUT1 DS).
Conclusions of the evaluation
In their evaluation, the HAS emphasizes the importance of early detection in preventing irreversible neurological damage. The METAglut1™ test, designed for ease of use and reliability, facilitates this early diagnosis through a simple blood sample, making it a valuable tool for healthcare providers.
This recognition by the HAS not only validates our commitment to advancing diagnostic solutions but also enhances the credibility of the METAglut1™ test within the medical community. We are proud to contribute to the fight against Glut1 Deficiency Syndrome and are excited about the potential impact our test can have on patient care.
About the Haute Autorité de Santé (HAS)
The Haute Autorité de Santé (HAS) is the french National Authority for Health, a highly respected authority that plays a crucial role in assessing the efficacy and safety of medical technologies.
Their analysis of the METAglut1™ test highlights its potential to aid providing accurate and timely diagnoses for patients suffering from Glut1DS, a condition primarily affecting children and caused by a defect in the GLUT1 glucose transporter.
As we continue to improve our offerings and expand our reach, we encourage healthcare professionals and institutions to explore the benefits of the METAglut1™ test. Together, we can work towards better outcomes for patients affected by metabolic disorders.
